Drug Type Antibody drug conjugate (ADC) |
Synonyms AB-3A4 |
Target |
Action inhibitors |
Mechanism KAAG1 inhibitors(Kidney-associated antigen 1 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Discovery | Canada | 01 Sep 2022 |






